Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status

Human Molecular Genetics

Volumn 13, Issue 23, 2004, Pages 2959-2969

  Hirota, Takeshi ^a   Ieire, Ichiro ^b   Takane, Hiroshi ^b   Maegawa, Shinji ^c   Hosokawa, Masakiyo ^d   Kobayashi, Kaoru ^d   Chiba, Kan ^d   Nanba, Eiji ^c   Oshimura, Mitsuo ^c   Sato, Tetsuo ^d   Higuchi, Shun ^a   Kenji, Otsubo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; MESSENGER RNA; TESTOSTERONE;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME METABOLISM; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID HYDROXYLATION;

ALLELES; BASE SEQUENCE; CPG ISLANDS; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HUMANS; LIVER; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 9744261674     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/ddh313     Document Type: Article

References (53)

1. Thummel, K.E. and Wilkinson, G.R. (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol., 38, 389-430.
2. Li, A.P., Kaminski, D.L. and Rasmussen, A. (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology, 104, 1-8.
3. Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491.
4. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423.
5. Lown, K.S., Thummel, K.E., Benedict, P.E., Shen, D.D., Turgeon, D.K., Berent, S. and Watkins, P.B. (1995) The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther., 57, 16-24.
6. Ozdemir, V., Kalowa, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L. and Kashuba, A.D. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373-388.
7. Rebbeck, T.R., Jaffe, J.M., Walker, A.H., Wein, A.J. and Malkowicz, S.B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. [Erratum (1999) J. Natl Cancer. Inst., 91, 1082.] J Natl Cancer. Inst., 90, 1225-1229.
8. Ball, S.E., Scatina, J., Kao, J., Ferron, G.M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P.J., Warner, N. et al. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther., 66, 288-294.
9. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T.B. and Ingelman-Sundberg, M. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun., 259, 201-205.
10. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W., Raunio, H., Crespi, C.L. and Gonzalez, F.J. (2000) CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther., 67, 48-56.
11. Wandel, C., Witte, J.S., Hall, J.M., Stein, C.M., Wood, A.J. and Wilkinson, G.R. (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4* 1B5′-promoter region polymorphism. Clin. Pharmacol. Ther., 68, 288-294.
12. Eiselt, R., Domanski, T.L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., Zanger, U.M., Brockmoller, J., Klenk, H.P., Meyer, U.A. et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458.
13. Brannan, C.I. and Bartolomei, M.S. (1999) Mechanisms of genetic imprinting. Curr. Opin. Genet. Dev., 9, 164-170.
14. Constancia, M., Pickard, B., Kelsey, G. and Reik, W. (1998) Imprinting mechanisms. Genet. Res., 8, 881-900.
15. Cooper, D.W., Johnston, P.G., Watson, J.M. and Graves, J.A.M. (1993) X-inactivation in marsurpials and monotremes. Semin. Dev. Biol. 4, 117-128.
16. Yan, H., Yuan, W., Velculescu, V.E., Vogelstein, B. and Kinzler, K.W. (2002) Allelic variation in human gene expression. Science, 297, 1143.
17. Pastinen, T., Sladek, R., Gurd, S., Sammak, A., Ge, B., Lepage, P., Lavergne, K., Villeneuve, A., Gaudin, T., Brandstrom, H. et al. (2004) A survey of genetic and epigenetic variation affecting human gene expression. Physiol. Genomics, 16, 184-193.
18. Horike, S., Mitsuya, K., Meguro, M., Kotobuki, N., Kashiwagi, A., Notsu, T., Schulz, T.C., Shirayoshi, Y. and Oshimura, M. (2000) Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing as essential role in Beckwith-Weidemann syndrome. Hum. Mol. Genet., 9, 2075-2083.
19. Brooks, B.A., McBride, O.W., Dolphin, C.T., Farrall, M., Scambler, P.J., Gonzalez, F.J. and Idle, J.R. (1988) The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1. Am. J. Hum. Genet., 43, 280-284.
20. Spurr, N.K., Gough, A.C., Stevenson, K. and Wolf, C.R. (1989) The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter. Hum. Genet., 81, 171-174.
21. Okita, C., Meguro, M., Hoshiya, H., Haruta, M., Sakamoto, Y.K. and Oshimura, M. (2003) A new imprinted cluster on the human chromosome 7q21-q31, identified by human-mouse monochromosomal hybrids. Genomics, 81, 556-559.
22. Lo, H.S., Wang, Z., Hu, Y., Yang, H.H., Gere, S., Buetow, K.H. and Lee, M.P. (2003) Allelic variation in gene expression is common in the human genome. Genome Res., 13, 1855-1862.
23. Reik, W. and Walter, J. (1998) Imprinting mechanisms in mammals. Curr. Opin. Genet. Dev., 8, 154-164.
24. Tilghman, S.M. (1999) The sins of the fathers and mothers: genomic imprinting in mammalian development. Cell, 96, 185-193.
25. Evans, H.K., Wylie, A.A., Murphy, S.K. and Jirtle, R.L. (2001) The neuronatin gene resides in a 'micro-imprinted' domain on human chromosome 2-q11.2. Genomics, 77, 99-104.
26. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P.B., Daly, A., Wrighton, S.A., Hall, S.D. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 27 383-391.
27. Tirona, R.G., Lee, W., Leake, B.F., Lan, L.B., Cline, C.B., Lamba, V., Parviz, F., Duncan, S.A., Inoue, Y., Gonzalez, F.J., Schuetz, E.G. and Kim, R.B. (2003) The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 9, 220-224.
28. Goodwin, B., Hodgson, E. and Liddle, C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339.
29. Johnson, R.F., Mitchell, C.M., Giles, W.B., Walters, W.A. and Zakar, T. (2002) The in vivo control of prostaglandin H synthase-2 messenger ribonucleic acid expression in the human amnion at parturition. Clin. Endocrinol. Metab., 87, 2816-2823.
30. Johnson, R.F., Mitchell, C.M., Giles, W.B., Walters, W.A. and Zakar, T. (2003) The control of prostaglandin endoperoxide H-synthase-2 expression in the human chorion laeve at term. J. Soc. Gynecol. Investig., 10, 222-230.
31. Weber, M., Hagege, H., Lutfalla, G., Dandolo, L., Brunel, C., Cathala, G. and Forne, T. (2003) A real-time polymerase chain reaction assay for quantification of allele ratios and correction of amplification bias. Anal. Biochem., 320, 252-258.
32. Hsieh, K.P., Lin, Y.Y., Cheng, C.L., Lai, M.L., Lin, M.S., Siest, J.P. and Huang, J.D. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos., 29, 268-273.
33. Eap, C.B., Buclin, T., Hustert, E., Bleiber, G., Golay, K.P., Aubert, A.C., Baumann, P., Telenti, A. and Kerb, R. (2004) Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur. J. Clin. Pharmacol., 60, 231-236.
34. Garcia-Martin, E., Martinez, C., Pizarro, R.M., Garcia-Gamito, F.J., Gullsten, H., Raunio, H. and Agundea, J.A. (2002) CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin. Pharmacol. Ther., 71, 196-204.
35. Mitsuya, K., Sui, H., Meguro, M., Kugoh, H., Jinno, Y., Niikawa, N. and Oshimura, M. (1997) Paternal expression of WT1 in human fibroblasts and lymphocytes. Hum. Mol. Genet., 6, 2243-2246.
36. Jinno, Y., Yun, K., Nishiwaki, K., Kubota, T., Ogawa, O., Reeve, A.E. and Niikawa, N. (1994) Mosaic and polymorphic imprinting of the WT1 gene in humans. Nat. Genet., 6, 305-309.
37. Nishiwaki, K., Niikawa, N. and Ishikawa, M. (1997) Polymorphic and tissue-specific imprinting of the human Wilms tumor gene, WT1. Jpn J. Hum. Genet., 42, 205-211.
38. Schweifer, N., Valk, P.J., Delwel, R., Cox, R., Francis, F., Meier-Ewert, S., Lehrach, H. and Barlow, D.P. (1997) Characterization of the C3 YAC contig from proximal mouse chromosome 17 and analysis of allelic expression of genes flanking the imprinted Igf2r gene. Genomics, 43, 285-297.
39. Dao, D., Frank, D., Qian, N., O'Keefe, D., Vosatka, R.J., Walsh, C.P. and Tycko, B. (1998) IMPT1, an imprinted gene similar to polyspecific transporter and multi-drug resistance genes. Hum. Mol. Genet., 7, 597-608.
40. Sy, S.K., Ciaccia, A., Li, W., Roberts, E.A., Okey, A., Kalow, W. and Tang, B.K. (2002) Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur. J. Clin. Pharmacol. 58, 357-365.
41. Gonzales, F. and Lee, Y. (1996) Constitutive expression of hepatic cytochrome P450 genes. FASEB J., 10, 1112-1117.
42. Wang, J.C., Stafford, J.M., Scott, D.K., Sutherland, C. and Granner, D.K. (2000) The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis. J. Biol. Chem., 275, 14717-14721.
43. Ourlin, J.C., Jounaidi, Y., Maurel, P. and Vilarem, M.J. (1997) Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. J. Hepatol., 26 (Suppl. 2), 54-62.
44. Rodriguez-Antona, C., Bort, R., Jover, R., Tindberg, N., Ingelman-Sundberg, M., Gomez-Lechon, M.J. and Castell, J.V. (2003) Transcriptional regulation ofhuman CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma. Mol. Pharmacol., 63, 1180-1189.
45. Burk, O. and Wojnowski, L. (2004) Cytochrome P450 3A and their regulation. Naunyn. Schmiedebergs. Arch. Pharmacol., 369 105-124.
46. Yan, H. and Zhou, W. (2004) Allelic variations in gene expression. Curr. Opin. Oncol., 16, 39-43.
47. Hardison, R.C., Oeltjen, J. and Miller, W. (1997) Long human-mouse sequence alignments reveal novel regulatory elements: a reason to sequence the mouse genome. Genome Res., 7, 959-966.
48. Jaenisch, R. and Bird, A. (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet., 33, S245-S254.
49. Sleutels, F., Zwart, R. and Barlow, D.P. (2002) The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature, 415, 810-813.
50. Finta, C. and Zaphiropoulos, P.G. (2000) The human cytochrome P450 3A locus. Gene evaluation by capture of downstream exons. Gene 260, 13-23.
51. Wojnowski, L. and Brockmoller, J. (2004) Single nucleotide polymorphism characterization by mRNA expression imbalance assessment. Pharmacogenetics, 14, 267-269.
52. Frommer, M., McDonald, L.E., Millar, D.S., Collis, C.M., Watt, F., Grigg, G.W., Molloy, P.L. and Paul, C.L. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA, 89, 1827-1831.
53. Yoshimoto, K., Echizen, H., Chiba, K., Tani, M. and Ishizaki, T. (1995) identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol., 39, 421-431.